You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD1

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Objective Response Rate Trial in Wuhan (GM-CSF)

Recruiting
  • Objective Response Rate
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Feb 25, 2023

HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

Recruiting
  • HLA-A2 Positive Cells Present
  • Refractory Melanoma
  • Alpha-type-1 Polarized Dendritic Cells
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 12, 2022

Head Neck Cancer, Intratumoral Injection Trial in Chicago (RiMO-301)

Recruiting
  • Head Neck Cancer
  • Intratumoral Injection
  • Chicago, Illinois
    University of Illinois at Chicago
Apr 28, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Carotid Artery Plaque, Pd-1 Inhibitors Trial in Hangzhou (PD-1 inhibitor)

Recruiting
  • Carotid Artery Plaque
  • Pd-1 Inhibitors
  • PD-1 inhibitor
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital of Zhejiang University, School of
Sep 17, 2022

Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Triple Negative Breast Cancer Trial in France (Ezabenlimab + BI907828)

Not yet recruiting
  • Adult Soft Tissue Sarcoma
  • +4 more
  • Ezabenlimab + BI907828
  • Bordeaux, France
  • +5 more
Oct 19, 2023

Unresectable Intrahepatic Cholangiocarcinoma Trial (Camrelizumab, Gemcitabine Injection, Cisplatin injection)

Not yet recruiting
  • Unresectable Intrahepatic Cholangiocarcinoma
  • (no location specified)
Feb 17, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Rectal Cancer Trial (PD-1, SCRT, Bevacizumab)

Not yet recruiting
  • Rectal Cancer
  • (no location specified)
Dec 6, 2022

Gastric Cancer Trial (Fruquintinib+PD-1)

Not yet recruiting
  • Gastric Cancer
  • (no location specified)
Feb 1, 2023

Oropharyngeal Cancer Trial in Shanghai (Toxicities reduced treatment, Conventional treatment)

Recruiting
  • Oropharyngeal Cancer
  • Toxicities reduced treatment
  • Conventional treatment
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and

Not yet recruiting
  • Colorectal Neoplasms
  • Beijing, Xicheng Dis, China
    Beijing Friendship Hospital, Capital medical University
Sep 5, 2023

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:

Not yet recruiting
  • Hepatocellular Carcinoma Non-resectable
  • transarterial therapies
  • (no location specified)
Nov 27, 2022

Hepatocellular Carcinoma Trial in Beijing (Sintilimab, Lenvatinib, radiotherapy)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Beijing Tsinghua Changgung Hospital
Jan 5, 2023

Oral Cancer, PD-1 Trial in Guangzhou (PD-1 with chemo, upright surgery)

Recruiting
  • Oral Cancer
  • PD-1
  • PD-1 with chemotherapy
  • upright surgery
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Nov 12, 2023

Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)

Recruiting
  • Gastric Cancer
  • HER2-low-expressing Gastric Cancer
  • Shanghai, China
    Shanghai East Hospital
Oct 9, 2023

Hepatocellular Carcinoma, HCC, Liver Cancer Trial in Hong Kong (Nivolumab, Hepatectomy)

Completed
  • Hepatocellular Carcinoma
  • +2 more
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Jul 20, 2022

Advanced Solid Tumor Trial in Xuzhou (Oncolytic Virus Injection(Revottack)+PD-1)

Not yet recruiting
  • Advanced Solid Tumor
  • Oncolytic Virus Injection（Revottack）+PD-1
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Dec 1, 2022

Lung Cancer Trial in Tianjin (PD-1 inhibitor, PARP inhibitor)

Recruiting
  • Lung Cancer
  • PD-1 inhibitor
  • PARP inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
May 23, 2022

Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

Recruiting
  • Melanoma (Skin)
  • +4 more
  • Bloomington, Minnesota
  • +7 more
Jan 31, 2023

Esophagus Cancer, Bladder Cancer, Liver Cancer Trial (Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal

Not yet recruiting
  • Esophagus Cancer
  • +4 more
  • Intravenous injection of P-IL-2
  • P-IL-2 plus Anti-PD-1 Monoclonal Antibody
  • (no location specified)
Apr 24, 2023

NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy Trial in Chengdu (Low Dose Radiotherapy, stereotactic body

Not yet recruiting
  • NSCLC
  • +3 more
  • Low Dose Radiotherapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Nov 11, 2022